Pharmaceuticals, Biotechnology & Life Sciences

Merck KGaA’s Q3 dip: trade tariffs, patent cliffs and U.S. expansion shape its strategy—boosting supply‑chain resilience, targeted M&A, and a 4.2% growth outlook.

BB Biotech Q3 2026: modest NAV rise, share price narrowing, 12 new positions, 3 FDA approvals, AI‑driven strategy driving value.

Explore Crown’s €46/share tender for QIAGEN—how a $4.6bn buy could merge advanced diagnostics with pharma to speed precision medicine and clinical trials.

MT’s 67 % gain over 3 years shows strong growth for Mettler‑Toledo International; discover how precision‑measurement tech fuels investor returns and sector resilience.

Long‑term LTE results show duvakitug maintains high remission rates in ulcerative colitis and Crohn’s disease, with a solid safety profile and early fibrostenotic CD signals.

Abivax SA’s clinical‑stage biotech profile: analyst buy ratings, institutional buying, and a promising obefazimod pipeline promise growth amid revenue shortfalls and reimbursement challenges.

Chugai Pharmaceutical Q3 2026 earnings reveal modest growth, a focus on core drugs, and regulatory opportunities in rare‑disease and AI diagnostics—what investors need to know.

Biogen beats earnings, fuels analyst optimism, and gains momentum in renal medicine with EMPAVELI and felzartamab—boosting investor confidence and market outlook.

BB Biotech’s Q3 performance shows strategic reinvestment into high‑potential biotech deals, driving NAV growth and shaping future reimbursement and patient access in healthcare.

Eurofins Scientific’s Europe Investor Day on Oct 23 reveals strong earnings, share‑purchase activity, and a future outlook that reinforces its leadership in analytical testing.